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PENGENALPASTIAN PENANDA BIOLOGI DAN PEMBANGUNAN KAEDAH 
PENYARINGAN UNTUK PENYAKIT BATU GINJAL 
 
 
ABSTRAK 
Penyakit batu ginjal adalah ganguan urologi yang paling biasa berlaku di 
kalangan lelaki dan wanita tetapi dengan lebih tinggi kelaziman di kalangan 
lelaki. Peluang masa hayat bagi seseorang mempunyai satu batu ginjal adalah 
lebih kurang 10% dan risiko ulangan dalam tempoh masa 10 tahun adalah 
74%. Dengan itu, terdapat satu keperluan yang besar bagi membangunkan 
suatu kaedah penyaringan untuk pengesanan penyakit batu ginjal. 
Dalam kajian ini, pendekatan proteomik digunakan untuk pengekstrakan, 
pengasingan dan pengenalpastian protein daripada subjek sihat, pesakit batu 
ginjal dan pesakit batu ginjal rekuren. Protein daripada urin diestrak dengan 
menggunakan teknik pemendakan garam dan estrak protein itu dilarutkan 
dalam penimbal pelarut. Campuran tersebut diasingkan mengikut jisim molekul 
masing-masing dengan menggunakan SDS-PAGE. Gel tersebut seterusnya 
diwarnakan dengan Coomassie Biru. Imej gel itu direkod dan dianalisis dengan 
menggunakan satu sistem pengimejan. Jalur-jalur sasaran protein dipotong 
daripada gel dan protein tersebut dicernakan oleh tripsin secara Dalam-gel. 
Peptida-peptida triptik seterusnya dikeluarkan daripada gel dan dianalisis 
dengan menggunakan LC/MS/MS, ia membolehkan penjujukan asid amino bagi 
peptida-peptida yang dianalisis. Spektrum produk ion yang diperolehi daripada 
MS/MS dicari dengan menggunakan enjin pencarian pengkalan data protein 
Mascot untuk pengenalpastian protein. Sejumlah dua puluh sembilan jenis 
protein telah dikenalpastikan daripada subjek sihat, pesakit batu ginjal dan 
pesakit batu ginjal rekuren. THP daripada urin dikenalpastikan sebagai satu 
 xx
penanda biologi untuk pesakit batu ginjal dan telah disahkan oleh Western 
blotting. 
Dengan mengguna THP sebagai penanda, kaedah-kaedah SDS-PAGE 
dan ELISA dibangunkan untuk kuantifikasi THP dalam urin. Bagi analisis SDS-
PAGE, sampel urin dimendak dengan garam dan dipekat sepuluh kali. Nilai 
penggalan bagi perkumuhan THP dalam urin untuk SDS-PAGE adalah 1.30 
mg/mmol. Walau bagaimanapun, sampel urin untuk analisis ELISA dicairkan 
sepuluh kali dalam penimbal sampel. ELISA yang dibangunkan mencapai 
kelinearan antara julat 109.33 μg/mL sehingga 945.67 μg/mL. Tambahan lagi, 
ketepatan asai adalah antara 98 – 101%. Kepersisan asai adalah kurang 
daripada 4% (C.V.) bagi kebolehulangan dan kurang daripada 5% (C.V.) bagi 
kebolehasilan. Kespesifikan dan kepekaan asai masing-masing adalah 86% 
dan 80%. Nilai penggalan bagi kepekatan THP dalam urin untuk ELISA adalah 
37.00 μg/mL dan 41.20 μg/mL masing-masing bagi lelaki dan perempuan.  
SDS-PAGE menunjukkan satu penggalan yang lebih jelas antara subjek 
sihat dan pesakit batu ginjal apabila dibandingkan dengan ELISA. SDS-PAGE 
adalah kaedah kuantitatif yang lebih baik untuk menentukan amaun THP dalam 
urin. 
 
 
 
 
 
 
 
 xxi
IDENTIFICATION OF BIOMARKER AND DEVELOPMENT OF SCREENING 
METHOD FOR KIDNEY STONE DISEASE 
 
ABSTRACT 
 
Kidney stone disease is the most common urological disorders that 
occurred in both men and women but with higher prevalence in men. The 
lifetime chance of an individual having a stone in kidney is approximately 10% 
and the risk of recurrence during 10 years period is 74%. Therefore, there is a 
great need to develop a screening method for detection of kidney stone 
disease. 
In this study, proteomic approach was used for extraction, separation 
and identification of urinary proteins from healthy subjects, stone formers and 
recurrent stone formers. Urinary proteins were extracted using salt precipitation 
technique and the protein extract was dissolved in solubilizing buffer. The 
mixture was separated according to their molecular weights using SDS-PAGE. 
The gel was then Coomassie Blue stained. The image of the gel was captured 
and analyzed by using an imaging system. The target protein bands were 
excised from the gel and proteins were digested In-gel by trypsin. The tryptic 
peptides were then eluted from the gel and analyzed using LC/MS/MS which 
allows amino acid sequencing of the analyzed peptides. The acquired MS/MS 
product ions spectrum was search against Mascot protein database search 
engine for protein identification. A total of twenty nine proteins were identified 
from healthy subjects, stone formers and recurrent stone formers. The urinary 
THP was identified as a biomarker for kidney stone disease and was confirmed 
by Western blotting. 
 xxii
Employing THP as biomarker, SDS-PAGE and ELISA methods were 
developed for urinary THP quantification. For SDS-PAGE analysis, the urine 
sample was salt precipitated and concentrated ten times. The cut-off value of 
THP excretion by SDS-PAGE was 1.30 mg/mmol. However, urine sample for 
ELISA analysis was diluted ten times in sample buffer. The developed ELISA 
achieves linearity within the range of 109.33 ng/mL to 945.67 ng/mL of THP. In 
addition, the assay accuracy was around 98 – 101%. The assay precisions 
were less than 4% (C.V.) for repeatability and less than 5% (C.V.) for 
reproducibility. The assay specificity and sensitivity were 86% and 80%, 
respectively. Whilst the cut-off values of THP concentration by ELISA were 
37.00 μg/mL and 41.20 μg/mL for male and female, respectively.  
SDS-PAGE shows a clearer cut-off between healthy subjects and stone 
formers as compared to ELISA. SDS-PAGE is a better method to quantify the 
amount of urinary THP. 
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CHAPTER ONE 
INTRODUCTION  
 
1.1 Kidney Stone Disease 
Kidney stone disease or known as nephrolithiasis is a common 
problem especially in industrialised nations. It is defined as one or more stones 
namely aggregate of crystals mixed with protein matrices, which are formed in 
the kidney or in the ureter (Figure 1.1). This may cause obstruction of urine flow 
in the renal collecting system, ureter or urethra which causes severe pain, 
bleeding or local erosion of kidney tissue (Tiselius et al., 2002).  
 
 
Figure 1.1: Formation of kidney stone in the kidney and ureter 
(MedicineNet.com, 2005). 
Kidney 
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1.1.1 Epidemiology of Kidney Stone Disease 
 Kidney stone disease affects 1 - 20% of the general population. 
According to data provided by the U.S. National Health Interview Survey (1990 - 
1992) approximately 1 million people suffered from stone disease yearly.  In 
Asia, its lifetime incidence is 2 - 5% (Barbas et al., 2002). 
The incidence and prevalence of kidney stone also varies in proportion 
to age, race and gender. Kidney stone disease afflicts both men and women but 
with higher prevalence in men than in women. The lifetime chance of an 
individual having a stone is 10 - 15% and the peak age of onset is 20 - 30 years 
old (Sandhu et al., 2003b). The risk of recurrence is 74% within 10 years for the 
first-time stone formers (Lewandowski and Rodgers, 2004) and therefore 
increasing the risk of permanent kidney damage despite modern techniques of 
stone removal. 
 
1.1.2 Aetiology and Pathogenesis  
Formation of stone in kidney is a complex and multifactorial process. It 
is a crystallization process taking place in supersaturated urine, where the urine 
substances form crystals that stick together and subsequently grow into stones 
on the inner surface of the kidney (Hess and Kok, 1996).  There are four types 
of stones namely calcium stones, struvite stones, uric acid stones and cystines 
stones. Calcium stones are the most predominant that compose 75% of all 
stones (Bihl and Meyers, 2001). The recurrence of calcium stone is greater than 
other types of kidney stones. 
A number of chemical and physical factors are known as active 
participants in stone formation. There are three main factors relevant to stone 
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formation: supersaturation of urine with stone constituents, urinary matrix as 
well as concentration of inhibitors and promoters of crystal aggregation (Anne 
and Gill, 1999). In theory, when the concentration of stone constituents (calcium, 
oxalate and phosphate) reached saturation state, stone formation will be 
induced by association of small amounts of crystalloid to form nuclei 
(nucleation). The nuclei grows and aggregates on the surfaces of collecting 
ducts and renal papillary epithelium (Bihl and Meyers, 2001; Tiselius, 1996). 
Renal epithelial cells specifically bind and internalize the crystal aggregates. 
Events that occur after crystal aggregates binding could be important in 
pathogenesis of stone i.e. cellular responses might be essential for the initiation 
of stone formation (Barbas et al., 2002). 
 Stone formation is inhibited by substances in urine that prevent 
crystallization. However it will only occur once the stone salts were exceeded. 
Saturation of urine with calcium oxalate is common in the population; therefore 
the role of other factors in the formation of stone must be crucial (Bihl and 
Meyers, 2001). For instance, although most people will achieve urinary 
supersaturation at some time yet only some will form kidney stone. The role of 
lithogenic risk factors including promoters and inhibitors is to predispose stone 
formers or to protect non-stone formers. Other important factor is uric acid 
which can precipitate persistently in acidic urine even in the absence of 
hyperuriceamia (an excess of uric acid in blood) or hyperuricosuria (an excess 
of uric acid in urine) (Barbas et al., 2002). Catalyst-like ability of uric acid can 
cause formation of calcium oxalate stone without being incorporated into the 
crystals (Bihl and Meyers, 2001; Srinivasan et al., 2005). Likewise, urinary pH 
has an essential part in many inhibitor or promoter reactions (Tiselius, 1981). 
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Urine normally contains inhibitors (e.g., pyrophosphate, citrate and 
macromolecules) that prevent crystal growth. Macromolecular factors such as 
chondroitin sulphate and haparin are inhibitors to crystal aggregation (Tiselius, 
1996). Therefore, insufficient quantity of inhibitors that prevent crystallization or 
inhibitors fails to induce the necessary chemical reactions that prevent the 
formation of crystals is the initial step in the development of kidney stone. A 
number of urinary macromolecules have been investigated as potential inhibitor, 
one of which is Tamm Horsfall Glycoprotein (THP) or uromodulin (Schnierle et 
al., 1996).  
 
1.1.3 Clinical Presentation   
Kidney stone develops slowly and asymptomatic or silent until they 
begin to move down the urinary tract, producing either hematuria or some 
degree of urinary obstruction. It also causes pain which is the classic symptom 
associated with lodged stone (Bihl and Meyers, 2001). In acute ureteral colic, 
the pain is severe and often starts in the flank region and moves down to the 
groin. It may radiate to the groin or testes depending on the location of 
obstruction. In addition, nausea, vomiting, chills, fever and elevated blood 
pressure are common. The other classic symptoms are frequent urinate and 
dark urine. Complications of kidney stone are recurrence of stones, urinary tract 
infection, ureter obstruction, kidney damage and decrease or loss of function of 
the affected kidney (Sandhu et al., 2003b). 
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1.1.4 Diagnosis 
 Documentation of stone characteristic is extremely important (type, size 
and location) for therapeutic management of kidney stone disease. Preliminary 
evaluation should include urinalysis, urine culture and plain film of the abdomen 
(Bihl and Meyers, 2001). Diagnostic imaging like Plain Abdominal Radiography 
(KUB), Intravenous Urography (IVU) and ultrasound are used to confirm that the 
symptoms are caused by stone in the case of symptomatic kidney stone 
disease. X-ray or ultrasound can help to locate the stone and determine its size 
and shape. More than two-thirds of kidney stones are radiopaque and can be 
seen on radiogram. Not all radiopaque stones (up to 34%) can be seen on an x-
ray or ultrasound; some are too small and others may be obscured by bones or 
overlying bowel gas. Uric acid stones are particularly radiolucent because they 
do not absorb enough x-rays therefore must be detected by other means 
(Sandhu et al., 2003b).  
KUB is irreplaceable in the management of a known radiopaque 
ureteric calculus especially in planning extracorporeal shock ware lithotripsy 
(ESWL) or monitoring the progress of the stone fragments after ESWL. It is also 
more reliable for assessing stone status (Lingeman, 1996).  
 IVU remains the first-line investigation for suspected ureteric calculus. 
The radiographic findings are both simple to interpret and highly accurate in 
diagnosing renal obstruction. For stones in the pelvicalyceal system, its size and 
local anatomy can clearly defined. Although there is a risk of allergy and 
contrast nephropathy, IVU remains the gold standard for such identification (Bihl 
and Meyers, 2001). Ultrasound also used in management of stone, which can 
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indicate whether a stone is in the kidney or ureter and degree of any obstruction. 
Stone size can be measured directly on ultrasound (Sandhu et al., 2003b).  
Biochemical test such as blood and urine can identify the presence of 
infection and establish the stone's chemical composition. The presence of 
urinary crystals or minute amounts of blood (microhematuria) in microscopic 
examination, either finding provides strong evidence of kidney stones (Parks 
and Coe, 1997).   
Furthermore, for recurrence kidney stones including any with a 
radiologic evidence of new stone formation, an increase in size of a pre-existing 
stone or passage of stone in the past year. However, most of the kidney stone 
disease is idiopathic, indicating the absence of any identifiable clinical cause of 
the disease and without discernible biochemical and/or anatomical abnormality 
(Lewandowski and Rodgers, 2004).  
 
1.1.5 Management of Kidney Stone Disease 
Management of kidney stones depends on the clinical presentation, 
stone location and size (Bihl and Meyers, 2001). With an acute presentation, 
the presence of complication such as secondary infection or renal impairment 
may necessitate immediate intervention. While, uncomplicated cases can be 
managed conservatively with adequate fluids and analgesia. In both cases, if 
the stone does not pass spontaneously, definitive stone treatment is required 
and is often performed as delayed and elective procedure (Sandhu et al., 
2003a). Blockage of urine flow requires emergency drainage that can be 
achieved by placement of retrograde stent when the kidney stone fails to pass. 
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The advances in urological techniques have drastically altered 
management of patients with symptomatic kidney stones disease who require 
treatment. Most symptomatic upper urinary tract stones are small and occur in 
normal kidneys and pass spontaneously if it is less than 5 mm in diameter. 
However, up to 80% of stones are greater than 5 mm in diameter and are 
needed to be removed by surgery or treated with ESWL (Lingeman, 1996). The 
percutaneous nephrolithotomy (PNCL) (Sandhu et al., 2003a) approach is best 
suited for removal of large and complex stones, whereas ESWL is a non-
surgical technique that uses high energy shock wave to break the large stones 
into small fragments that will pass through urinary system (Erhard et al., 1996). 
 
1.2 Organic Matrix of Kidney Stones 
Kidney stones compose of an outer crystalline phase which mostly 
contains urate, calcium, oxalate and phosphates. The inner core of the stone 
contains organic stone matrix, which derived from a variety of sources including 
macromolecules of kidney and serum origin, exfoliated epithelial cells, cells 
originating in blood and urinary proteins (Khan and Hackett, 1993). 
One of the main theories concerning stone formation in the kidney is 
matrix theory (Van Aswegen and Du Plessis, 1991). According to the matrix 
theory, urinary proteins such as uromucoid promote precipitation of calcium 
oxalate and/or calcium phosphate crystals. Urinary proteins may act as binding 
surface for inorganic ions and thus provide a framework for deposition of stone 
salts (calcium, oxalate, phosphate and etc). Thus, the concentration of urinary 
proteins may play an integral role in stone formation. 
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Organic matrix of kidney stone has long been investigated yet its 
functional significant relationship to the kidney stone development remains 
obscure. A better understanding of the components of stone matrix and their 
interaction on the molecular level seems mandatory in order to gain better 
insight of stone formation. The effects of specific urinary macromolecules on 
calcium oxalate crystallization have been evaluated by Rose and Sulaiman 
(1982) and Drach et al. (1982). The authors explained that mucoprotein and 
mucopolysaccharides may act as promoters for stone formation and as 
enhancers for nucleation because of their ability to bind calcium. The organic 
matrix of the kidney stone accounts for 2 to 3% of total stone weight as reported 
by Sugimoto et al. (1985). Some matrix components play significant role in 
stone formation while others do not. The organic matrix of kidney stone mainly 
contains macromolecules derived from urine, which may serve as inhibitors to 
the formation of stone. There are variety of urinary macromolecules presence in 
urine and organic matrix of stone. The macromolecules reported were 
nephrocalcin (14 kDa), fibronectin (230 kDa), prothrombin fragment 1 (32 kDa), 
osteopontin (67 kDa) and THP (95 kDa). Thus, urinary macromolecules were 
suggested to be the major component of the organic matrix of kidney stones 
(Govindaraj and Selvam, 2002). Nevertheless, most of the stone proteins have 
not been fully characterized, which is due to the difficulties in isolating them in 
their native form. Although various methods including gel permeation 
chromatography and high performance liquid chromatography for the separation 
of proteins from organic stone matrix have been carried out, these methods 
could not completely isolate the proteins. Consequently, a complete profile of 
renal stone proteins is not available to date.    
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1.3 Urinary Proteins of Kidney Stone Disease 
Human urine is formed in kidney via ultrafiltration from the plasma to 
eliminate waste products such as urea and metabolites. Components in the 
ultrafiltrate are selectively reabsorbed result in less than 1% of ultrafiltrate is 
excreted as urine. Urine production under normal physiologic conditions is 1 - 2 
L/day however it also depends on fluid intake (Adachi et al., 2006). 
The glomerular filtrate has a similar composition of plasma except that 
it is almost free of proteins. Almost all the protein on the glomerular filtrate is 
reabsorbed and catabolized by proximal convoluted tubular cells, which result in 
the excretion of urinary protein less than 150 mg/24 hour (Adachi et al., 2006; 
Christensen and Gburek, 2004). Thus, the amount of protein presence in urine 
is very low. 
The concentration of urinary macromolecules that may serve as 
inhibitors or promoters is one of the main factors for formation of stone. The 
involvement of urinary macromolecules (urinary proteins) as inhibitors to the 
formation of stone was reported by researchers. Most of the urinary 
macromolecules are anionic with many acidic residues and frequently contain 
posttranslational modifications such as phosphorylation and glycosylation 
(Lafitte et al., 2002). They exert inhibitory effects by binding to crystals and 
consequently inhibit the adhesion of crystals to renal epithelial cell. Amongst the 
urinary macromolecules reported are nephrocalcin (14 kDa), an acidic protein of 
tubular cells origin. Nephrocalcin in the kidney stone patients’ urine is lacking of 
gamma-carboxyglutamic acid (GLA) residues which reduce its ability to inhibit 
crystals nucleation and calcium aggregation (Nakagawa et al., 1987). 
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Fibronectin (230 kDa): it is a multifunctional alpha 2-glycoprotein that 
distributed throughout the extracellular matrix and body fluids. Recent studies 
have demonstrated that it is excreted from tubular cells and its secretion can be 
stimulated by calcium oxalate crystals (Tsujihata et al., 2000). It may inhibit 
calcium oxalate crystals aggregation and their attachment to tubular cells 
(Tsujihata et al., 2000). 
 Prothombin fragment 1 or crystal matrix protein (32 kDa): It is a 
peptide generated from sequential cleavage of prothrombin. There is an 
increasing evidence reported that urinary prothrombin fragment 1 plays a 
contrasting roles involved in early stage of stone formation as both the active 
participant and the inhibitor of calcium oxalate nucleation, growth and 
aggregation (Grover and Ryall, 1999). 
Osteopontin or uropontin (67 kDa): In a crystal matrix, osteopontin has 
several biological functions including involvement in biomineralization and stone 
formation (Denhardt and Guo, 1993). Amino acid sequence of osteopontin 
contains a high proportion of aspartic acid residues, which binds calcium and is 
strongly associated with calcium oxalate crystals. Therefore, osteopontin has 
been suggested to be potent inhibitor to calcium oxalate crystallization and may 
also involve in crystal retention of crystallization in the kidneys (Fouad et al., 
1998). 
Tamm Horsfall glycoprotein (THP), (85 kDa): THP may play an 
important role in stone formation and has great potential to serve as biomarker 
for detection of kidney stone disease (Schnierle et al., 1996). 
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1.4 Tamm Horsfall Glycoprotein (THP) 
In 1950, Tamm and Horsfall discovered a glycoprotein in urine, which 
was named as Tamm Horsfall Glycoprotein (THP). THP is the most abundant 
glycoprotein present in the urine of healthy subjects (Tamm and Horsfall, 1950). 
THP is secreted by the thick ascending limb of the loop of Henle (Gokhale et al., 
1996; Muchmore and Decker, 1985). THP inserted into luminal cell surface by 
the glycosyl-phosphatidylinositol (GPI)-anchor and then excreted in urine at a 
rate of 50 - 100 mg/day (Cavallone et al., 2001; Kumar and Muchmore, 1990). 
Thus, THP is a glycosylphosphatidylinositol (GPI)-anchored protein.  
Muchmore and Decker (1985) identified a 85 kDa uromodulin in the 
urine of pregnant women. Uromodulin is commonly known as THP (Pennica et 
al., 1987). The author explained that its molecular mass, abundance  in urine 
and characteristic resembled with THP (Muchmore and Decker, 1985). In 
addition, uromodulin was reported to possess the same amino acids structure of 
THP (Pennica et al., 1987). However, its carbohydrate contents especially 
mannose chains and physiological function are slightly different from THP 
(Devuyst et al., 2005). 
 
1.4.1 THP Structure 
THP is a monomeric glycoprotein of approximately 85 kDa but has a 
strong tendency to form macroaggregates of several million Daltons. It has 639 
amino acids and 48 cysteine residues. In addition, it contains about 30% 
carbohydrate and heavily glycosylated by polyantennary sialated N-linked 
glycans (Fletcher et al., 1970; Pennica et al., 1987). The sialic acid may play an 
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important role to maintain THP function in kidney stones formation (Knörle et al., 
1994).  
 
1.4.2 Physiological Function 
The physiological function of THP still remains unclear. It has been 
suggested that it may play an important role in maintaining water permeability of 
the thick ascending limb of the loop of Henle due to its gel forming properties 
(Menozzi et al., 2002). It may also act as an adhesion molecule and involve in 
stone formation where it is present in the core of the stones (Tamm and Horsfall, 
1950). It may also protect urinary system from uropathogens by inhibiting 
bacterial adherence. As explained by Pak  et al. (2001), THP exerts a protective 
role against Escherichia coli colonization by competing for glycans carried by 
membrane glycoproteins of the urinary tract, e.g., uroplakin. According to this 
hypothesis, the infectious disease in urinary tract could have acted as selective 
agents for the large release of urinary THP from the kidney. Thus, THP is 
essential for the normal physiological function of kidneys. 
 
1.4.3 The Role of THP Glycomoiety in Renal Disease 
THP glycomoiety has been indicated to be responsible for the binding 
with adhesins of pathogenic strains of Escherichia coli (Pak et al., 2001), 
whereby prevent an individual from infectious disease. In addition, THP 
glycomoiety has been proposed to be involved in the renal diseases. There are 
differences in the carbohydrate composition of the THP isolated from renal 
disease patients and from the healthy subjects (Olczak et al., 1999a), where 
THP isolated from the patients has alternation of its oligosaccharide chains that 
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affects its biological activity. Olczak et al. (1999b) described that THP of renal 
disease patients reacted more weakly with lectins, which is specific for terminal 
oligosaccharides. In addition, THP has been reported to be responsible for 
pathological conditions such as tubulointerstitial nephritis, recurrent calcium 
oxalate stone and nephropathy due to its ability to precipitate with other proteins 
(Olczak et al., 1999a; Olczak et al., 1999b). 
 
1.4.4 The Role of THP on Stone Formation 
In relation to kidney stone disease, THP has been shown to be 
present in the core of calcium oxalate kidney stone as reported by Grant et al. 
(1973). However, it is not clear whether it is a passive support or an active 
participant in stone formation. The findings of crystallization assays that 
developed with the aim of elucidating the role of THP on stone production are 
controversial. Scurr and Robertson (1986)  explained that THP might acts as an 
inhibitor or promoter of stone formation as previously proposed by Rose et al. 
(1982). However, Sophasan et al. (1980) claimed that THP has no effect in 
stone formation. 
THP was implicated as both an inhibitor and promoter of stone 
formation (Hess et al., 1989; Sikri et al., 1981). Its inhibitory properties arose by 
coating crystals, retarding the attachment of new crystals and thus preventing 
crystals growth and aggregation. However, self-aggregation and polymerisation 
of THP is caused by high calcium concentration, high ionic strength and low pH 
(Stevenson and Kent, 1970), which allow the protein to act as a promoter by 
forming a mesh to which crystals adhere and thus initiate crystal growth .  
 14
Hess et al. (1989) described that THP is the major inhibitor of calcium 
oxalate crystal aggregation in the urine of healthy subjects. However, stone 
formers excreted defective urinary THP that diminish its inhibitory effect on 
stone formation (Hess et al., 1989). Taking into account those observations, it 
has been suggested that not only defective THP but a decreased THP excretion 
may facilitate the development of kidney stones. Nevertheless, the molecular 
basis of the urinary THP abnormality in stone formers needs further elucidation.  
In the studies of Knörle et al. (1994), the authors reported that THP 
from the healthy subjects was more glycosylated with sialic acid than the 
recurrent stone formers. The terminal sialic acid is essential for the inhibitor 
function of THP in healthy subjects, however this function was diminished in the 
recurrent stone formers owing to their THP lack of sialic acid (Knörle et al., 
1994). In 2001, Chen et al. demonstrated that THP exhibits inhibitory effect on 
stone formation. Thereafter, Carvalho et al. (2002) agreed that the inhibitory 
effect of THP is related to sialic acid. Therefore, carbohydrate structure of THP 
is the major feature that may regulate kidney stone formation. 
 
1.4.5 Assays Used for THP Measurement 
In accordance with these preliminary studies, THP evidently is a good 
candidate that may act as biomarker for detection of kidney stone disease. 
Therefore, researchers have been ventured variety of highly sensitive and 
specific assays to quantify THP, which was considered as a potential biomarker 
for kidney stone disease. There are large numbers of assays developed. 
Amongst these are electroimmunodiffusion, gel electrophoresis, 
radioimmunoassay and enzyme-linked immunosorbent assay (ELISA).  
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In a study, Boyce and Swanson (1955) showed that the amount of 
urinary THP excreted was constant in the healthy subjects, however it was 
increased in the stone formers (Boyce and Swanson, 1955). Bichler et al. (1975) 
explained that the Boyce and Swanson’s method using centrifuged and 
precipitated urine for THP measurement may lead to less reliable results. This is 
because aggregated and non-aggregated forms of THP have different solubility 
in salts solution and their proportions in urine are unknown (Bichler et al., 1975). 
As a consequent, the electroimmunodiffusion was developed by  
Bichler et al. (1975) and Samuell (1979) for THP measurement. Both of the 
authors reported that no significant difference between healthy subjects and 
stone formers. The average THP excretion in urine was 40 - 50 mg/day (Bichler 
et al., 1975; Samuell, 1979). However, Bichler et al. (1999) described that there 
are significantly decrease of THP excretion in uric acid stones patients, 
staghorn calculi or renal tubular acidosis. The authors explained that damage of 
distal and proximal tubular epithelial cells in some of the stone formers who 
prone to develop uric acid stones.  
A rapid and specific radioimmunoassay was developed by Hunt et al. 
(1985) for THP quantification. The authors reported that there were no 
differences between THP concentration in fresh and frozen urine samples after 
dialysis. However, freezing of dialysed urine before analysis can alter the 
protein structure and make the THP concentration more variable. 
The THP quantification has been limited by the laborious and relatively 
insensitive assay. Pretreatment of urine samples were included before assay 
such as dialysis, gel filtration, ultracentrifugation, freezing, incubation with 
detergents and adjustment of pH (Dawnay et al., 1982). 
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Therefore, Dawnay et al. (1982) investigated factors that affecting 
THP quantification in order to improve the developed radioimmunoassay. The 
THP concentration was affected by osmolality, THP concentration and pH of the 
urine. Consequently, the 24 hours urine sample was extensively diluted in water 
(100 dilutions) before assay.  The author found that THP level was not affected 
by the variation in THP concentration and pH of urine. This indicated that 
soluble form of THP was attained (Dawnay et al., 1982).  
Lynn et al. (1982) determined the amount of urinary THP excretion by 
using radioimmunoassay. The authors claimed that the amount of THP excreted 
was not influenced by exercise, age, diuresis and amounts of calcium or sodium 
excreted (Lynn et al., 1982). 
Romero et al. (1997) developed an ELISA  to quantify urinary THP 
concentration. The urine sample was frozen at -20oC before assay and series of 
diluted urine sample were incubated overnight in the assay.  The authors found 
that THP excretion in the recurrent stone formers was significantly decreased 
when comparing to healthy subjects.  
Currently, there is a commercially available ELISA kit (Synelisa THP 
assay). The ELISA kit uses 24 hour urine sample for THP excretion 
measurement. Using this kit, Ganter et al. (1999) investigated the THP excretion 
and its correlation  to citrate in urine of stone formers. Both are potent factors in 
the kidney stone forming process. THP excretion in stone formers was 
significantly lower as compared to healthy subjects (Ganter et al., 1999). The 
authors found that THP excretion was positively correlated to citrate. Thus, the 
decrease of THP in stone formers may indicate tubular dysfunction (Lynn and 
Marshall, 1984). 
 17
Glauser et al. (2000) also used the commercial ELISA kits  to 
investigate urinary excretion of THP and to identify possible determinants of 
urinary THP excretion in stone formers and healthy subjects. In both of the 
healthy subjects and stone formers, urinary THP excretion was related to body 
size, renal function and urinary citrate excretion whereas dietary habits do not 
affect THP excretion (Glauser et al., 2000). THP excretion in uric acid stone 
formers and staghorn calculi were found lower than healthy subjects, In addition, 
the decrease of THP excretion in uric acid stone formers was reported by  
Bichler et al. (1999). 
The major obstacle for accurate measurement of THP is aggregation 
of THP that exists in various polymeric forms in urine. Hence, Kobayashi and 
Fukuoka (2001) have tried to resolve the problem by solubilizing urinary THP 
using Triton X 100, EDTA and alkaline pH instead of conventional buffer such 
as phosphate buffer saline (PBS) prior to ELISA analysis. The authors showed 
that the combination of Triton X 100, EDTA and alkaline pH is the best 
solubilizing buffer for THP.  
Although immunoassay is selective and sensitive, it relies on the 
availability of specific polyclonal or monoclonal antibodies. Therefore, a lectin 
affinity bioassay without using antibodies was developed by Topcu (2002) to 
quantify the cytolytic activity of THP. The author employed lectin in the assay; 
lectin was suggested to have strong interaction toward THP and therefore the 
binding is proportional to the amount of THP involved in cytolytic activity. In view 
of this finding, the specific interaction of lectin and THP indicating lectin was 
used as capture material for development of ELISA. 
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1.4.6 Interaction of Lectin with THP 
 Lectins are glycoprotein of 60,000 - 100,000 Da molecular weights, 
which are known for their ability to recognize and bind certain types of 
carbohydrate residues. Most lectins are multimeric consist of non-covalently 
associated subunits. A lectin may contain two or more of the same subunit or 
different subunits (Pisztai, 1991). 
In addition, lectins are classified as unique group of proteins that 
attributed with specific carbohydrate binding sites. Thus, interaction of each 
lectins toward a particular carbohydrate structure is very specific, even 
oligosaccharides with identical sugar compositions can be distinguished (Boyd, 
1962; Pisztai, 1991).  
Lectin determinants in the carbohydrate moieties of glycoproteins 
have specific ligands for lectin binding. The reactivity of lectin is represented by 
binding power of the combination of two individual sugars (Wu, 2003). The 
interaction between a lectin and its receptor may vary greatly as a result of 
small changes in the carbohydrate structure of the receptor (Boyd, 1962). Thus, 
carbohydrate moieties of lectin are responsible for many biological functions.  
 Wu et al. (1995a) reported that THP in either native or its desialylated 
(asialo) contain important receptors for Triticum vulgaris (WGA). The sialic acid 
and its configuration impose on the oligosaccharide chains is of major important 
for the interaction with WGA. However, the interaction was lost after removal of 
sialic acid (Wu et al., 1995a; Wu et al., 1995b). Sherblom et al. (1988) explained 
that the strong interaction between THP and WGA is mediated by carbohydrate 
residues. Abbondanza et al. (1980) reported that the interaction between lectin 
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and THP is due to the carbohydrate specificity of lectin and the high affinity of 
oligosaccharide chains of THP for the lectin.  
The interaction of WGA to lectin receptor of THP is very specific and 
unique as if antigen-antibody or enzyme substrate interactions. Due to this 
reason, the WGA can be used as reagents for characterization of THP. 
Therefore, WGA can be used as capture material for development of an ELLSA 
to quantify urinary THP level. 
 
1.5 Urinary Proteome 
Urinary proteome is a term that represents the full protein profile of 
urine from the healthy individual. The content of urinary proteome contains not 
only plasma proteins but also kidney proteins (Pieper et al., 2004; Pisitkun et al., 
2004). Thus, urine can be very useful in clinical diagnostics as well as a 
potential source of biomarkers (Thongboonkerd, 2004). Urine is excreted daily 
from human body and therefore it can be obtained in large quantity. Although 
some of the biomarker present at low concentration in urine, they may be 
enriched in order to achieve the measurable concentration. Another advantage 
of using urine for diagnosis is it allows continual collection of test sample over 
lengthy time periods (Adachi et al., 2006; Smith et al., 2005).   
Urinary proteome provides sufficient information about the disease 
process affecting the entire renal tubules (Pieper et al., 2004). The pattern of 
urinary protein changes as a result of diseases particularly those affecting the 
kidney. In general, normal urinary proteins reflect a normal tubular physiology, 
however information of changes in urinary proteins excretion by various 
interventions is essential to provide better understanding about the tubular and 
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glomerular responses to physiological stimuli (Thongboonkerd, 2004). In order 
to discover novel disease biomarker of urinary proteome in human urine, both 
qualitative and quantitative analysis of a large number of patients and healthy 
subjects’ urine are needed (Pieper et al., 2004).  
Previously, the combination of SDS-PAGE and Western blotting were 
employed by using unconcentrated urine to map urinary protein of renal disease 
(Kshirsagar and Wiggins, 1986). The author found that many proteins in urine 
migrate with similar molecular weights and some proteins are not detected by 
silver stain. In addition, the specific identification of individual proteins using 
Western blotting is not feasible and limited by the availability of antibodies 
(Kshirsagar and Wiggins, 1986).  
 Recently, the advancement of mass spectrometry may be useful in 
complementing gel electrophoresis approach for identification of urinary 
proteins (Baldwin, 2004). Thus, the complete urinary proteome may be 
achieved. The mass spectrometry even is a powerful tool to discover biomarker 
of renal disease such as kidney stone. The state-of-the-art technologies 
integrated with protein enrichment technique, protein separation method and 
mass spectrometry (MS) should be conducted for biomarker discovery and 
protein analysis (Adachi et al., 2006). There are various protein enrichment 
techniques that can be used to concentrate urinary proteins. In many other 
studies, gel electrophoresis (SDS-PAGE or 2-D gel electrophoresis) was 
employed to separate and map protein expression at qualitative and 
quantitative level (Kshirsagar and Wiggins, 1986; Smith et al., 2005).  Using this 
method, protein expression of the sample obtained from healthy and diseased 
individuals can be compared. The appearance and disappearance of spots or 
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bands can provide information about differential protein expression, while the 
intensity of those spots or bands provides quantitative information about protein 
expression (Graves and Haystead, 2002). Thus, gel electrophoresis remains an 
essential component of proteomics. Furthermore, liquid chromatography mass 
spectrometry (LC/MS/MS) and/or Western blotting can be used to identify and 
characterize the urinary proteome (Thongboonkerd, 2004).  
 Spahr et al. (2001) applied gel electrophoresis and LC/MS/MS to 
identify proteins from unfractionated urine of healthy subjects. The authors 
stated that construction of urinary proteome map may provide useful information 
regarding differentially expressed proteins between the healthy and disease 
state. Hence, the urinary proteins pattern either in healthy subjects or patients 
should be consistent and comparative. In addition, Lafitte et al. (2002) 
described that the pattern of urinary proteins are specific either in healthy 
subjects or renal disease patients. Pisitkun et al. (2004) reported analysis of the 
urinary proteome of healthy subjects identified several proteins known to be 
involved in renal and systemic disease. 
 The database of urinary proteome is gradually expanded by the 
progressive investigation and studies. The goals are to build fundamental 
knowledge of renal physiology to define the pathophysiology of renal diseases 
and to identify novel biomarkers or new therapeutic targets. Thus, identification 
of an unique protein that is present either in healthy subjects or patients may a 
good candidate of biomarker (Pieper et al., 2004).  
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1.5.1 Biomarker  
Biomarker or biological marker is defined as a characteristic that is 
measured and evaluated objectively as an indicator of normal biological 
processes, pathological processes or pharmacologic responses to therapeutic 
intervention (Biomarker Definition Working Group, 2001).   
Biological fluids were suggested to reflect the ensemble of tissues 
present within a patient. The discovery of biomarker in biological fluids which is 
disease specific becomes a great challenge. In view of the fact that biological 
fluids do not have a corresponding genome or transcriptome that permits gene 
expression to be measured, DNA- or RNA-based diagnostics are not applicable 
to biological fluids (Anderson and Anderson, 2002). Therefore, proteomics 
approach is one of the few options for identifying biomarker in biological fluids. 
In some cases, the biomarkers of interest can be present in low concentration 
levels and masked by a high abundance protein or cover a wide range of 
chemical space, making the challenge to be great and critical (Drexler et al., 
2004). However, proteomics analysis has greatly increased our knowledge on 
the protein content of clinical important biological fluids. 
 
1.5.2 Discovery of Biomarker Using Proteomics Analysis 
Proteomics analysis of biological fluids is commonly applied to 
distinguish the diversity protein content in sample obtained from patients with 
specific disease and healthy subjects (Issaq et al., 2003). Initially, protein profile 
of healthy and specific disease individuals is compared to identify unique 
proteins which either presence in healthy or diseased individual. Subsequently, 
the proteins are digested by protease and then subjected to mass spectrometry 
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analysis. The mass spectrometry analysis can be categorized into biomarker 
discovery and proteomics diagnostic approach (Issaq et al., 2003). In the 
biomarker discovery approach, liquid chromatography is coupled with tandem 
mass spectrometry (MS/MS) to identify peptides that are unique or highly 
abundant in samples obtained from patients with specific disease state 
compared with healthy subjects. This approach generates copious of data and 
identify hundreds of proteins. However, it is very time consuming and hence 
limited number of comparative samples can be analyzed (Issaq et al., 2003).  
In the proteomics diagnostic approach, samples from healthy and 
disease affected individuals are applied to proteins chips that are modified with 
specific chromatographic resin. Subsequently, mass spectra of the bound 
proteins obtained and differences in peak intensities between sample sets are 
ascertained by bioinformatics algorithms (Petricoin et al., 2002). Most of the 
proteomics diagnostic approach does not reply on the actual identification of the 
specific protein(s) within the peak through which the diagnosis is determined, 
although identification of the selected peak can be pursued. This method 
becomes very popular due to its high throughput nature (Issaq et al., 2003). 
 
1.5.3 Identification and Validation of Biomarker 
The identification of a target protein is performed by comparative 
searches using protein databases or de novo sequencing. For a biomarker to 
be effective, it is necessary to accurately measure the small changes in 
intensities of the biomarker (most of the time at low level) in a complex matrix 
repeatedly on a large number of samples. Hence, the possible deviation of the 
results due to sample handling and the analytical technique itself need to be 
 24
kept at a minimum by developing a highly sensitive and quantitative analytical 
assay (Drexler et al., 2004). Therefore, appropriate sample preparation 
techniques (e.g., extraction, isolation and purification) and a suitable mass 
analyzer should be applied for monitoring of the biomarker. 
Three important steps was suggested as a general guideline for 
comprehensive analysis of biomarker discovery: (1) protein isolation to remove 
abundant proteins such as albumin and immunoglobulin without exclude other 
proteins that may alter the whole urinary proteome, (2) protein separation to 
reduce the complexity of the protein mixture and (3) peptide sequencing with 
high accuracy and rapid scanning (Drexler et al., 2004).  
Recent advancement in mass spectrometry integrated with gel 
electrophoresis, LC and/or multidimensional liquid chromatography (LC/LC) 
strategies have led to remarkable improvement in the ability for disease 
biomarker discovery. Thus, the combined techniques were used to identify and 
subsequently validate biomarker in the biological fluids.  
Quantitative protein expression profiling is a vital part in the proteomic 
analysis of healthy versus disease state. This will be the best option for protein 
quantification particularly in gel electrophoresis (SDS-PAGE or 2-D gel 
electrophoresis) where multiple proteins are present in one spot or band. Since 
tracking the protein responsible for differential staining is difficult, therefore 
changes in the protein expression level can be measured directly from mass 
spectrometry of a peptide ion derived from the protein (Graves and Haystead, 
2002). 
Typically, LC/MS/MS is performed to identify proteins and peptides 
sequence (Coon et al., 2005). The difference in intensity abundance of the 
